STUDresearch · Peptide

SS-31

Also known as

Elamipretide · Elamipretide HCl · Bendavia · MTP-131 · MTP131 · Forzinity (FDA brand for Barth syndrome) · Szeto-Schiller peptide 31 · Szeto-Schiller 31 · D-Arg-Dmt-Lys-Phe-NH2

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Peptide Lots of talk Systemic SubQ; clinical IV Mitochondrial & metabolic peptides

Systemic — mitochondria-targeting tetrapeptide studied by SubQ and IV routes; Forzinity is a narrow Barth-syndrome prescription path.

What people say SS-31 is elamipretide, a mitochondria-targeting tetrapeptide. FORZINITY is FDA-approved through the accelerated pathway for muscle-strength improvement in Barth syndrome patients weighing at least 30 kg; that narrow disease use does not validate gray-market longevity or performance protocols. Doses people talk about

Inspected lower-dose discussion1–4 mg SubQ daily

Several ME/CFS commenters described amounts in this range with outcomes spanning fatigue, no change and quieter energy; illness, pacing, dose changes and products varied.

Inspected 4 mg report4 mg SubQ once daily

One Reddit author reported a rapid morning effect after nearly a month; other authors in the same thread reported no effect or materially different responses.

Inspected higher-dose report8–20 mg SubQ daily

One author described splitting higher daily amounts into two or three injections after months of use; subjective energy later became subtler and product identity was unverified.

FORZINITY label40 mg SubQ once daily

Approved for Barth syndrome patients weighing at least 30 kg; not a general longevity or performance dose.

Community rows are descriptive, product identity is generally unverified, and reports conflict. The labeled disease regimen applies only to its indicated population and formulation.

Half-life & effect duration

Half-life in the body: Elamipretide · plasmaAbout 3–4 hours
Felt duration people report: Positive reportsEnergy or recovery changes within minutes, on day 1 or after weeks
Other accountsNo change, fading acute effects after months or severe fatigue

Timing context & sources

How it may feel Community reports conflict sharply: some describe immediate or morning energy and less fatigue, others describe severe fatigue, GI symptoms, headache, heat or no change. Same-author updates in one ME/CFS thread also mixed dose changes, pacing and crashes, so no typical onset or duration is established.

Cycles people discuss The approved Barth path is continuous daily SubQ treatment, while PMM trials used four- or 24-week blocks. Community four-to-twelve-week blocks, pauses and SS-31-before-MOTS-c sequences are convenience and lore, not a proven healthy-user cycle. Timing The labeled Barth-syndrome path uses once-daily SubQ treatment, while community notes place unverified wellness use in the morning or near training without a controlled winner. Those contexts are not interchangeable. Stacks MOTS-c, humanin, NAD-axis compounds and mitochondrial supplements are commonly discussed beside SS-31, but no preserved combination RCT establishes synergy, sequence or shared-syringe compatibility. Multi-agent energy reports cannot isolate SS-31. Watch for Injection-site reactions (dominant AE): Redness/erythema, pain, itch/pruritus, swelling, induration, bruising, hemorrhage, urticaria — top trial and community issue.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

FDA review reports an approximately 3–4-hour human plasma elimination half-life for elamipretide.

For SubQ administration, the approved label reports Tmax of 0.5–1 hour, about 92% absolute bioavailability, minimal accumulation and near-complete urinary recovery of parent plus inactive metabolites by 48 hours.

The plasma half-life does not measure mitochondrial-membrane residence, duration of subjective energy or the safety of gray-market products and off-label populations.

FDA multidisciplinary review — NDA 215244 FORZINITY (elamipretide) (opens in a new tab)FDA review states an approximately 3–4-hour plasma elimination half-life and summarizes SubQ absorption, renal excretion, minimal accumulation and the 40 mg dose-selection rationale.Regulatory synthesis spans clinical formulations and populations; the PK value does not establish tissue duration, subjective onset or off-label benefit.
FDA — FORZINITY (elamipretide) prescribing information (opens in a new tab)Approved label gives the Barth-syndrome indication and 40 mg SubQ once-daily regimen for patients weighing at least 30 kg; each 0.5 mL dose contains 40 mg from the 280 mg/3.5 mL (80 mg/mL) single-patient-use vial. It also reports 0.5–1-hour Tmax, 92% bioavailability, minimal accumulation and approximately 100% urinary recovery of parent plus M1/M2 by 48 hours in patients with normal renal function.The label is indication- and formulation-specific; it does not validate healthy-user dosing, gray-market identity or subjective energy claims.

Felt duration people report

No consistent onset or duration of perceived energy, fatigue or recovery emerged from the inspected community discussions.

Reports ranged from minutes or the first day to weeks, no change, waning acute effects after months and severe fatigue; one same-author ME/CFS chronology mixed dose changes, pacing and crashes.

Anonymous reports involve different illnesses, stacks, amounts, products and follow-up; unverified identity and expectation effects prevent causal or prevalence estimates.

Reddit r/cfs — SS-31: your experiences? I'll share mine (opens in a new tab)Large multi-author thread contains same-author updates and contrasting reports of fatigue, GI symptoms, heat, headache, no change or energy across roughly 0.1–20 mg, with pacing, ME/CFS and several stacks disclosed.Anonymous, self-selected discussion with unverified products, heterogeneous illness, changing amounts, multiple co-treatments and no blinded comparator.
Reddit r/Peptides — SS-31: Dosing and Results? (opens in a new tab)Multiple authors report 0.5–4 mg daily, no noticeable effect, morning energy, less fatigue and other varied outcomes; one much higher-dose account adds adverse observations and uncertain attribution.Anonymous multi-author thread with unverified products, self-reported amounts, differing health conditions and no controlled comparator or reliable prevalence estimate.

What people say 17

Energy / fatigue (users): Community logs often claim steadier daytime energy, less mid-day crash, or easier recovery over multi-week daily or near-daily SC — highly confounded by stacks and training. forum
Exercise capacity (anecdote): Some performance logs claim better work capacity or zone-2 feel; not large-RCT primary endpoints in healthy athletes. anecdote
ME/CFS experiment talk: Occasional long-form anecdotes claim outsized energy/cognition response; also frequent null reports — not trial-backed for that indication. anecdote
vs NAD+ axis: Often described as structure (SS-31) + substrate/cofactor (NMN/NR/NAD+) — stack logic is mechanistic storytelling, not combined Phase 3 data. forum
Stack confound: Benefits logged with MOTS-c ± humanin ± NAD+ ± CoQ10/PQQ are hard to attribute to SS-31 alone. forum
Barth / TAZPOWER: Small randomized crossover used 40 mg SC daily × 12 weeks per arm with a 4-week washout; open-label extension (OLE) continued 40 mg SC daily for long horizons (reports up to ~168 weeks). trial
Barth OLE signals: Sustained 6-minute walk test (6MWT) gains from OLE baseline (published cumulative ~96 m at week 168 in completers), fatigue scores below baseline, and 3D cardiac volume trends (stroke/EDV/ESV) discussed as improving over long follow-up. trial
FDA basis (2025): Forzinity accelerated approval to improve muscle strength (knee-extension strength pathway) in genetically confirmed Barth syndrome weighing ≥30 kg — not a general longevity indication. trial
PMM MMPOWER (IV short course): Dose-escalation IV (0.01 / 0.1 / 0.25 mg/kg/h × 2 h × 5 days) showed dose-related 6MWT movement; highest-dose cohort often cited for ~placebo-adjusted walk gains after 5 days. trial
PMM MMPOWER-2 (SC): 40 mg SC daily × 4 weeks crossover (n≈30): 6MWT +~19.8 m vs placebo (p≈0.083, not significant on primary); fatigue PROs (PMMSA Total Fatigue, Neuro-QoL Fatigue) improved more on drug. trial
PMM MMPOWER-3 (pivotal): 40 mg SC daily × 24 weeks failed to improve co-primary 6MWT and fatigue vs placebo in the broader PMM population — major bro/clinic talking point that “40 mg SC is not a guaranteed mito win.” trial
HFrEF (stable): Randomized placebo vs 4 mg vs 40 mg SC daily × 28 days did not improve LVESV (primary) or LVEF vs placebo despite good tolerability. trial
STEMI / reperfusion: EMBRACE-STEMI-type IV peri-PCI programs did not meet overall infarct-size primary; subgroups sometimes discussed in reviews, not community wellness dosing. trial
Dry AMD / GA pipeline: ReCLAIM-2 and follow-on Phase 3 (ReNEW / ReGAIN) interest centers on ellipsoid-zone / retinal endpoints — separate from SC longevity stacks. trial
Cardiolipin / ROS (preclinical): Animal and in-vitro work shows better mito ultrastructure, lower oxidative markers, and exercise-tolerance rescue in aged mice (classic rodent example: ~3 mg/kg/day × 8 weeks). animal
Kidney / ischemia: Rodent organ-protection data is frequently cited as rationale, not human proof for wellness use. animal
vs MOTS-c framing: SS-31 = membrane/cardiolipin “repair-stabilize”; MOTS-c = AMPK/metabolic signaling peptide — complementary lore, not a head-to-head RCT. forum

Doses people talk about 23

What most people mean: ~5–10 mg SC daily (sometimes ~5–20) is the longevity/biohack discussion band — not the labeled rare-disease dose. forum
Biohacker dose (most common discussion): ~5–10 mg subcutaneous daily; some run ~5–20 mg/day. Disease-label 40 mg/day is a different path. forum
Conservative start (community charts): Often ~2–5 mg SC once daily for the first 1–2 weeks to gauge site tolerance and subjective response. forum
Higher community / trial-matching: ~10–20 mg SC daily, with some escalating toward ~20–40 mg/day to “match disease trials” despite cost and ISR burden. forum
User-log distribution (anonymized trackers): Self-report buckets often pile into “5+ mg” per injection; lower mcg–low-mg buckets also appear. forum
Twice-weekly protocols: Some consumer guides push ~5 mg only 2×/week — far below trial daily SC exposure; debated as under-dosing relative to short half-life. forum
Pre-workout vs morning: Morning SC common for “day energy”; some time near training — no clear winner in controlled data. forum
Quality / fill flag: Gray-market lyophilized “SS-31” vials (often sold as 5 / 10 / 20 / 30 mg) are not pharmaceutical Forzinity on purity, identity, or fill accuracy — dose math assumes the label is true. forum
1–2 mg tune-up camp: 2026 YouTube/clinic-adjacent line: 40 mg is an engine-rebuild for a rare cardiolipin disease; healthy-user talk stays 1–2 mg or 5–10 mg. forum
Saturation lore: Some 2026 explainers claim binding/effect “saturates” around ~5–10 mg — mechanistic storytelling, not a healthy-adult PK study. forum
500 mcg vendor charts: A minority commerce chart still lists ~500 mcg/day 5-on/2-off — far below both the 5–10 mg biohack band and the 40 mg label. forum
Diminishing-returns logs: Reddit 2026: some feel 2–2.5 mg is “enough”; others felt nothing at 2–4 mg and only noticed ~5–10; a few say 5 vs 10 felt the same. forumanecdote
Ultra-low-dose camp: Influencer/forum claim that ~1–2 mg daily for 4–8 weeks is “enough for age-related decline” and that 40 mg is a genetic-disease dose only — contested; not a labeled wellness dose and not RCT-proven for healthy aging. forum
2026 high-dose craze (still not 40 mg default): X/forum 2026 includes “stop baby-dosing,” ~10 mg/day talk, and short 10–30 mg/day n=1s. Cost and ISR scale fast. Not a new Barth protocol. forumanecdote
Framing: All figures below are discussed trial, label, clinic, or community amounts — research/educational context only, not prescriptions or advice. forum
Barth / Forzinity label: 40 mg subcutaneously once daily for patients weighing ≥30 kg. trial
Renal label math: Adults with severe renal impairment (eGFR <30 mL/min) not on dialysis — labeled reduction to 20 mg SC daily; mild/moderate (eGFR ≥30) usually no change; dialysis not studied. trial
TAZPOWER / OLE: 40 mg SC once daily throughout randomized periods and long OLE (multi-year daily SC in remaining participants). trial
MMPOWER-2 / MMPOWER-3 SC: 40 mg SC once daily (4-week arms in MMPOWER-2; 24 weeks in MMPOWER-3). trial
HFrEF SC trial arms: 4 mg or 40 mg SC once daily × 28 days vs placebo — both tested; primary remodeling endpoint negative. trial
IV MMPOWER short course: 0.01, 0.1, or 0.25 mg/kg/h infused ~2 h daily × 5 days — roughly maps to low-single-digit to ~tens of mg/day depending on body weight and cohort. trial
Other IV cardiac programs: Infusion rates such as ~0.05 mg/kg/h (and related dose-finding ladders) appear in STEMI/HF IV literature — clinical setting only, not home protocols. trial
PK exposure note: Label-style PK summaries: roughly dose-proportional exposure over ~2–80 mg daily SC, minimal accumulation with once-daily dosing, absolute SC bioavailability ~92%. trial

How it may feel 8

Hours–day 1: Not a stimulant “kick.” Peak plasma after SC is often ~0.5–1 h; most people notice injection sting/redness more than systemic energy the first day. forum
Days 1–7: Often little systemic change; site reactions dominate early logs. A minority claim next-day recovery or morning energy early — anecdote only. forum
Weeks 1–2: Logs that later claim benefit often describe steadier mornings, fewer crashes, or slightly easier hard sessions — still easy to confabulate with sleep/caffeine/training. forum
Weeks 3–4: Common personal checkpoint to continue or stop (cost + daily needles). Aligns with short SC trial blocks (e.g., MMPOWER-2 4-week arms). forum
No change by ~4 weeks: Community advice usually re-checks sleep, iron/thyroid, training load, and stack noise before dose-chasing toward 40 mg. forum
After stop: Some report energy fading over days–weeks; residual fitness if training stuck. Short plasma half-life vs claimed longer membrane effects is the usual bro explanation. anecdote
Weeks 6–12: Matches many community “blocks” and TAZPOWER 12-week treatment windows; disease-trial functional curves are not healthy-user guarantees. trial
Months 2–6+: Barth OLE = chronic daily 40 mg with multi-month functional/cardiac trend data in a tiny rare-disease sample. Healthy-user multi-month continuous logs exist but are thinner and confounded. trial

Around the dose 6

Clock: Morning / daytime mito talk more than bedtime. forum
Training: Sometimes paired with the session as a mitochondrial-adjacent pin, not a pre-workout stimulant. forum
After: Move and sleep. SS-31 is not a night GH peptide in these threads. forum
Fasted: No locked empty-stomach rule in current SS-31 charts (unlike GH-axis). forum
Pre-workout vs morning: Morning or pre-session both appear; not a stimulant pre-workout. forum
Volume depends on formulation: Milligrams alone do not determine injection volume. Forzinity supplies 40 mg in 0.5 mL; gray-market vial concentration and identity vary, so no preparation or under-dosing inference follows from the amount alone. trialforum

Cycles people discuss 10

Biohacking blocks: Commonly 4–8 weeks or 8–12 weeks daily/near-daily SC, then reassess. forum
Time off patterns: 2–4 weeks off between blocks is frequently written into guides; sometimes longer off periods purely for cost. forum
Continuous vs pulsed debate: Clinical programs favor continuous daily SC; healthy-user practice often pulses around camps, travel fatigue, or training blocks because continuous multi-mg SC is expensive and needle-heavy. forum
Tolerance lore: No clear community consensus that “receptor desensitization” requires cycling; off periods are driven more by ISR fatigue, money, and thin healthy-user long-term data. forum
Re-runs: Common after weeks off; outcomes outside disease trials stay anecdotal. anecdote
Stack sequencing lore: Some run SS-31 alone 1–2 weeks then add MOTS-c; others reverse or rotate — no standard RCT sequence. forum
12 on / 4 off: Common 2026 wellness writeup for the 5–10 mg band — cost and site rotation, not a trial design. forum
Clinical disease path: Barth / Forzinity and TAZPOWER OLE = continuous daily SC for months to years, not classic bodybuilding on/off. trial
PMM trial blocks: MMPOWER-2 used 4 weeks on → 4 weeks washout → 4 weeks opposite arm; MMPOWER-3 used continuous 24 weeks on drug or placebo. trial
Quarterly-style consumer cycle: Some wellness pages describe ~3 months on / 1 month off, a few times per year — convenience framing, not trial design. forum

Timing 10

Downstream / membrane lore: Community argument is brief blood presence vs longer cardiolipin-binding / membrane effects after repeated daily dosing — plausible mechanism talk, not a measured “tissue half-life” for gray-market users. forum
Timing practicalities: Morning SC is most common; evening used when morning site pain bothers training. No proven superiority. forum
SC absorption: Maximum concentrations commonly ~0.5–1 hour after subcutaneous injection; thigh and abdomen exposures described as comparable for labeled product. trial
Bioavailability: Absolute SC bioavailability ~92% in label-style PK summaries. trial
Distribution: Rough volume of distribution ~0.5 L/kg (total body water scale); plasma protein binding ~39%. trial
Metabolism: Sequential C-terminal degradation to inactive M1 (tripeptide) and M2 (dipeptide) metabolites. trial
Elimination: Parent + M1 + M2 largely recovered in urine by ~48 hours in normal renal function — drives renal dose adjustment talk. trial
Measured human plasma elimination: FDA's multidisciplinary review states an approximately 3–4-hour plasma half-life for elamipretide. The approved label separately reports 0.5–1-hour SubQ Tmax, minimal accumulation and near-complete urinary recovery of parent plus M1/M2 by 48 hours. trial
Why still daily: Short-ish plasma residence + minimal multi-day accumulation + trial programs standardized on once-daily SC (especially 40 mg) even when half-life quotes conflict. trial
Washout planning: TAZPOWER used multi-week washout between crossover arms; MMPOWER-2 likewise used 4-week washout — used when people argue residual functional carryover. trial

Stacks 9

SS-31 + MOTS-c (top named mito stack): Framed as cardiolipin/ETC stabilization (SS-31) + AMPK/metabolic signaling (MOTS-c). Example community charts: SS-31 ~5–10 mg SC daily (or near-daily) with MOTS-c ~5–10 mg/week total (e.g., 500 mcg daily or ~1 mg EOD; higher weekly totals in some endurance writeups). No formal combined human RCT. forum
Stack schedule example (guides): Week 1 SS-31 alone ~5 mg/day, then add MOTS-c for weeks 2–5 while keeping SS-31 — one of many blog schedules, not a standard of care. forum
Mito triad: SS-31 + MOTS-c + humanin (or humanin analogs / SHLP-class talk) in advanced longevity threads. forum
NAD+ axis: NMN, NR, or injectable/IV NAD+ layered under SS-31 — heavily confounded “energy stack.” forum
CoQ10 / ubiquinol + PQQ + ALA: Non-peptide mito supplements frequently layered; CoQ10 framed as electron carrier while SS-31 stabilizes complexes. forum
Clinic energy protocols: Examples combine NAD+ IV 1–2×/week + MOTS-c 2–3×/week + SS-31 3–5×/week — multi-factor and not isolatable. forum
Separate vs mixed syringes: Most discussion prefers separate SC injections rather than mixing SS-31 and MOTS-c in one pen/syringe (stability/compatibility unproven in community practice). forum
Training + sleep: Outcome logs that look good often credit zone-2/strength consistency and sleep as much as the peptide. forum
Not a GH stack: Usually not grouped with CJC/Ipamorelin or growth-hormone secretagogue protocols except in kitchen-sink longevity lists. forum

Access talk 1

[object Object]

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 8

Watch for 19

Systemic nonspecifics: Headache, mild GI complaints, dizziness, flushing, transient nausea, or fatigue appear in trial tables and user logs — often hard to separate from stacks. forum
Source / identity risk: Gray-market contamination, underfill, wrong peptide, or degraded product is a separate risk layer from pharmaceutical trial safety. forum
Cost / adherence burden: Daily multi-mg SC is expensive and needle-intensive — intermittent under-dosing is common and muddies outcome stories. forum
Oral product skepticism: Community generally treats oral SS-31 as low-credibility vs SC for systemic exposure. forum
Don’t copy 40 mg because it’s FDA-approved: Approval is Barth ≥30 kg muscle-strength, not a longevity milligram. trialforum
Access / RUO vs Forzinity: Gray-market 5/10/20/50 mg vials are the biohack path; Forzinity is a labeled drug for a rare disease. forum
High-dose ISR + cost: 10 mg+ daily is where 2026 “craze” and dropout stories meet. forum
Injection-site reactions (dominant AE): Redness/erythema, pain, itch/pruritus, swelling, induration, bruising, hemorrhage, urticaria — top trial and community issue. trial
ISR frequency (trial scale): MMPOWER-2 reported injection-site reactions in ~80% on elamipretide (mostly mild). Broader trial summaries often put erythema/induration roughly in a ~40–60% band and pruritus ~30–45% depending on study/table. trial
Discontinuations: Higher AE-related dropouts on drug vs placebo in some SC programs (e.g., MMPOWER-3 reported higher discontinuation for AEs on elamipretide than placebo); site reactions drove real-world adherence friction. trial
Hypersensitivity: Serious allergic reactions requiring emergency care are noted in label-style warnings; hypersensitivity to drug or excipients is a contraindication-style caution. trial
Eosinophilia: Listed among adverse findings in some professional monographs (frequency not always tightly defined). trial
Benzyl alcohol (Forzinity): Multi-dose pharmaceutical solution contains benzyl alcohol (label discussion includes BA content per mL) — relevant for labeled product constraints and certain pediatric toxicity warnings around BA-containing injectables generally. trial
Indication limit: FDA path is Barth syndrome muscle-strength improvement in ≥30 kg patients only; longevity, sports, ME/CFS, and general mito-support uses are off-label / research-chem territory. trial
Mixed efficacy caution: Negative or non-confirmatory primaries in HFrEF remodeling and pivotal PMM (MMPOWER-3) mean “works for mitochondria” is not a free pass across indications. trial
Renal special populations: Adult severe renal impairment needs labeled dose rethink (20 mg vs 40 mg on Forzinity path); dialysis unstudied. trial
Weight / age access: Forzinity approval currently limited to ≥30 kg; sponsor discussed collecting more data for smaller children. trial
Pregnancy / unknown populations: Not established for broad wellness populations; disease labels and trials do not equal healthy-user safety proof. trial
Never risk-free framing: Even with a relatively large peptide trial safety database vs many research peptides, ISR burden, hypersensitivity potential, source risk, and indication-specific failures remain real. forum

Updated: 2026-09-01

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

What people say 17

Doses people talk about 23

How it may feel 8

Around the dose 6

Cycles people discuss 10

Timing 10

More on what it is 12

Stacks 9

Access talk 1

Storage notes 2

Related 8

Watch for 19

Timing context & sources